Funding Round attributes
Catalyst OrthoScience, a medical device firm based in Naples, Florida, has raised $20 million through a mix of equity and venture debt. The funding comes from a group of investors including RC Capital, Mutual Capital Partners, and Bridge Bank. Catalyst specializes in shoulder replacement technology, and this infusion of capital will be directed toward expanding distribution, hiring talent, and launching new products. Since its inception, Catalyst has made significant progress, with its products used in over 10,000 shoulder replacement surgeries. The company remains committed to improving surgical outcomes through innovative solutions.
Catalyst OrthoScience was founded with a mission to develop and commercialize shoulder replacement devices that offer less invasive procedures and better patient outcomes. Their flagship product, the Catalyst CSR Shoulder System, has been praised for its precision and the potential to reduce recovery times. With a growing presence in the orthopedic market, Catalyst aims to use the newly raised capital to further enhance its technology and expand its reach in the medical device industry.
The funds will support key growth initiatives, including the expansion of distribution networks and scaling operations to meet increasing demand for Catalyst’s shoulder replacement systems. Additionally, the company plans to introduce new products to the market that will build on its success and provide advanced solutions for orthopedic surgeons and patients.
According to the press release, Catalyst has already achieved notable milestones, including surpassing 10,000 successful shoulder arthroplasty procedures since its first case in 2016. The company’s commitment to innovation has positioned it as a key player in the shoulder replacement sector, with a focus on developing devices that are designed to improve patient outcomes while minimizing the complexity of surgical procedures.
